Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

>. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

For further information, please visit www.delmarpharma.com
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... biologics ... cancer, CAMBRIDGE, Mass., June 10 Merrimack Pharmaceuticals,Inc., a ... for autoimmune disease and cancer, today announced that it,has raised ... Existing and new investors participated in the financing including,Credit Suisse ...
... BHRT ) today announced that it has received ... the Nasdaq Capital Market. The Company,s,common stock will be ... Market at the opening of business on Wednesday, June ... the Nasdaq Stock Market for,companies with a lower market ...
... June 10 Miltenyi Biotec has,acquired Medic Tools ... strengthens the portfolio in the area of sample,preparation. ... into the product range of instruments, reagents, and ... Boris Stoffel and,Franz G. Bucher, Vice President and ...
Cached Biology Technology:Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Bioheart, Inc. to Transfer to Nasdaq Capital Market 2Miltenyi Biotec GmbH Acquires Medic Tools AG 2
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with the ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Environmentalists are just as fond of talking about ... "sustainability" has become a buzzword. The problem is that ... have manifold interpretations. Agricultural scientists at the Technische Universitaet ... colleagues in theoretical and applied science they have managed ...
... viral polymerase may provide a new therapeutic target for host-adapted ... "Spread of Infection and Lymphocyte Depletion in Mice Depends on ... of the American Journal of Pathology . Highly ... strain of the influenza virus that has adapted to infect ...
... An innovative approach to brain research developed by ... School at Houston has been selected for funding ... designed to support high-impact, medical investigations. Valentin ... at the UT Medical School at Houston, has ...
Cached Biology News:New tools for sustainable farming 2New tools for sustainable farming 3UT's Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research 2UT's Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research 3
The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
... these culture chambers produce cell yields in ... range and are useful alternatives to multiple ... mechanical • strength and structural integrity • ... Certified nonpyrogenic and sterilized by gamma irradiation, ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
...
Biology Products: